Abstract
ObjectiveThis work aims to analyze the 100 most cited papers in radiotherapy or chemoradiotherapy for cervical cancer.MethodsThe 100 most cited papers in radiotherapy or chemoradiotherapy between 1990 and 2020 were identified with Thompson Reuters Web of Science citation indexing on August 24, 2020. The publication years, source titles, countries/regions, total citations, and average citations per year were extracted from the Web of Science. The research type and research domain were classified by the authors.ResultsThese 100 papers were cited a total of 28,714 times, and the median number of citations was 169.5 (ranging from 116 to 1,700 times). The most cited paper was “Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer” by Rose et al., with a total citation of 1,700 times. The International Journal of Radiation Oncology Biology Physics (40 papers), Radiotherapy and Oncology (14 papers), and the Journal of Clinical Oncology (12 papers) published the largest number of papers. USA (47 papers), Austria (18 papers), Canada (13 papers), and England (13 papers) contributed the largest number of papers. Image-guided adaptive brachytherapy (IGABT) had the largest number of papers (25 papers). Concurrent chemotherapy was the most cited research domain, with 10,663 total citations and 592.4 citations per paper.ConclusionIn the present study, we conducted a bibliometric analysis of the 100 most cited papers in radiotherapy or concurrent chemoradiotherapy for cervical cancer in the past 30 years. IGABT and concurrent chemotherapy were the most cited research domains.
Highlights
Cervical cancer is one of the most common cancers globally, especially in countries with a middle/low human development index [1]
Among the 10 most cited papers (Table 1), there were five randomized clinical trials [6,7,8,9,10] and one metaanalysis [11] comparing cisplatin-based concurrent chemoradiotherapy and single radiotherapy in patients with cervical cancer, and there were two recommendations on image-guided adaptive brachytherapy (IGABT) released by the gynecological (GYN) GEC ESTRO Working Group [12, 13]
Between 1999 and 2000, five randomized clinical trials demonstrated that cisplatin-based concurrent chemoradiotherapy (CCRT) was superior to radiotherapy [6,7,8,9,10]
Summary
Cervical cancer is one of the most common cancers globally, especially in countries with a middle/low human development index [1]. Radiotherapy or chemoradiotherapy plays an important role in the treatment of cervical cancer. Adjuvant radiotherapy/concurrent chemoradiotherapy (CCRT) is performed in early-stage cervical cancer patients with risk factors. Definitive CCRT is the standard treatment approach in patients with locally advanced cervical cancer (LACC). Palliative/ salvage radiotherapy is conducted in patients with stage IVB or recurrent disease [2]. The staging and treatment strategy have changed dramatically in the past three decades. The FIGO staging system was revised in 1994, 2009 [3], 2014 [4], and 2018 [5]. Nodal status is incorporated into stage IIIC disease in the last FIGO staging system [5]. The treatment strategy for LACC changed from single radiotherapy to concurrent chemoradiotherapy. External beam radiation therapy has changed from conventional radiotherapy to intensity-modulated radiation therapy (IMRT) or conformal radiation therapy
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
